Physician profile
John Rhodes, JR.
NPI 1912060799
$7,579.06
in general payments reported to CMS, 2019-2025
11 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $382 · 2021: $741 · 2022: $251 · 2023: $798 · 2024: $1,221 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,740 · Travel and Lodging: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,740.00 |
| Travel and Lodging | $1,182.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,118.58 | 2021-2025 | Harmony, Concertotm |
| W. L. Gore & Associates, INC. | $1,782.64 | 2019-2024 | Gore Cardioform Septal Occluder |
| Cardiva Medical, INC. | $285.88 | 2024 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 5f Vcs |
| Abiomed | $137.20 | 2024 | Impella |
| Medtronic Vascular, INC. | $109.64 | 2019-2020 | |
| Boston Scientific Corporation | $34.02 | 2023 | |
| Abbott Laboratories | $29.25 | 2024 | Na |
| B. Braun Interventional Systems INC. | $22.30 | 2020 | |
| Edwards Lifesciences Corporation | $20.19 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cordis US Corp. | $19.76 | 2025 | Palmaz Genesis |
| Abbvie INC. | $19.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.